Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
by Richard Daverman, PhD
June 11, 2013 -- FortuneRock (China) Ltd., a privately held biopharmaceutical company located in Beijing, has sold non-exclusive US rights for a patented technology to an unnamed global top 10 pharmaceutical company. FortuneRock holds patents in the US and China for its novel recombinant human serum albumin fusion protein drug that is a long-acting treatment for neutropenia. FortuneRock is currently conducting a China Phase I/II trial of the drug in cancer patients with neutropenia. Financial details of the agreement were not disclosed. More details....
Help employers find you! Check out all the jobs and post your resume.
